SG11201811154QA - Method for producing diphenylmethane derivative - Google Patents

Method for producing diphenylmethane derivative

Info

Publication number
SG11201811154QA
SG11201811154QA SG11201811154QA SG11201811154QA SG11201811154QA SG 11201811154Q A SG11201811154Q A SG 11201811154QA SG 11201811154Q A SG11201811154Q A SG 11201811154QA SG 11201811154Q A SG11201811154Q A SG 11201811154QA SG 11201811154Q A SG11201811154Q A SG 11201811154QA
Authority
SG
Singapore
Prior art keywords
diphenylmethane derivative
producing diphenylmethane
producing
derivative
diphenylmethane
Prior art date
Application number
SG11201811154QA
Other languages
English (en)
Inventor
Hee-Kyoon Yoon
Se-Hwan Park
Ji-Sung Yoon
Soongyu Choi
Hee Jeong Seo
Eun-Jung Park
Younggyu Kong
Kwang-Seop Song
Min Ju Kim
So Ok Park
Original Assignee
Daewoong Pharmaceutical Co Ltd
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd, Green Cross Corp filed Critical Daewoong Pharmaceutical Co Ltd
Publication of SG11201811154QA publication Critical patent/SG11201811154QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D9/00Crystallisation
    • B01D9/005Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B51/00Introduction of protecting groups or activating groups, not provided for in the preceding groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201811154QA 2016-06-17 2017-06-15 Method for producing diphenylmethane derivative SG11201811154QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160075910 2016-06-17
PCT/KR2017/006271 WO2017217792A1 (ko) 2016-06-17 2017-06-15 다이페닐메탄 유도체의 제조방법

Publications (1)

Publication Number Publication Date
SG11201811154QA true SG11201811154QA (en) 2019-01-30

Family

ID=60664449

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201811154QA SG11201811154QA (en) 2016-06-17 2017-06-15 Method for producing diphenylmethane derivative
SG10201911782RA SG10201911782RA (en) 2016-06-17 2017-06-15 Method for producing diphenylmethane derivative

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201911782RA SG10201911782RA (en) 2016-06-17 2017-06-15 Method for producing diphenylmethane derivative

Country Status (29)

Country Link
US (2) US10640496B2 (ko)
EP (2) EP3663292B1 (ko)
JP (4) JP6763978B2 (ko)
KR (2) KR102233229B1 (ko)
CN (2) CN109311861B (ko)
AU (1) AU2017285813B2 (ko)
BR (1) BR112018076243A2 (ko)
CA (2) CA3026756C (ko)
CL (1) CL2018003645A1 (ko)
CO (1) CO2018014018A2 (ko)
DK (2) DK3473621T3 (ko)
DO (1) DOP2018000287A (ko)
EC (1) ECSP19000185A (ko)
ES (2) ES2898336T3 (ko)
HR (1) HRP20211670T8 (ko)
HU (1) HUE056428T2 (ko)
MA (2) MA50774B1 (ko)
MX (2) MX2021008988A (ko)
NZ (1) NZ749398A (ko)
PE (2) PE20240590A1 (ko)
PH (1) PH12018550206A1 (ko)
PL (2) PL3473621T3 (ko)
PT (2) PT3663292T (ko)
RS (1) RS62550B1 (ko)
SA (1) SA518400666B1 (ko)
SG (2) SG11201811154QA (ko)
SI (1) SI3663292T1 (ko)
TN (1) TN2018000437A1 (ko)
WO (1) WO2017217792A1 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011054773A1 (de) 2011-10-25 2013-04-25 Vb Autobatterie Gmbh & Co. Kgaa Anschlusspol für einen Akkumulator, Akkumulatorgehäuse und Maschine zur Herstellung eines Anschlusspols
PE20211206A1 (es) 2018-08-13 2021-07-05 Dae Woong Pharma Preparacion de intermedio util para la sintesis de inhibidor de sglt
CN112341416A (zh) * 2019-08-09 2021-02-09 天津津艺医药科技发展有限责任公司 一种制备苯并含氧脂杂环衍生物的方法
AU2021225706B2 (en) 2020-02-27 2024-06-13 Daewoong Pharmaceutical Co., Ltd. Intermediate useful for synthesis of SGLT inhibitor and method for preparing SGLT inhibitor using same
PE20231373A1 (es) 2020-09-10 2023-09-07 Daewoong Pharmaceutical Co Ltd Metodo de sintesis para la preparacion de un intermedio de inhibidores de sglt
CN112094253B (zh) * 2020-09-10 2023-01-10 株式会社大熊制药 用于制备sglt抑制剂中间体的合成方法
CN113200860A (zh) * 2021-04-29 2021-08-03 爱斯特(成都)生物制药股份有限公司 一种sglt2抑制剂中间体的制备方法
CN113801010A (zh) * 2021-11-18 2021-12-17 山东诚创蓝海医药科技有限公司 一种5-溴-2-氯苯甲酸的制备方法
CN113912487B (zh) * 2021-11-23 2024-05-28 山东研峰新材料科技有限公司 一种2,5-双卤代苯甲酸的合成方法
KR20230110001A (ko) 2022-01-14 2023-07-21 주식회사 대웅제약 Ssglt 저해제의 합성에 유용한 중간체의 제조 방법
KR20240044190A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 결정형 및 이의 제조방법
KR20240044194A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 공결정

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966907A (en) * 1988-08-12 1990-10-30 Merck & Co., Inc. 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis
AR045173A1 (es) * 2003-08-01 2005-10-19 Tanabe Seiyaku Co Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio
DK2183263T3 (da) 2007-07-26 2012-01-30 Lexicon Pharmaceuticals Inc Fremgangsmåder og forbindelser anvendelige til fremstilling af natriumglucose-cotransportør-2-inhibitorer
JP2011529477A (ja) 2008-07-30 2011-12-08 フエルレル インターナショナル,ソシエダッド アノニマ 1,6−ジヒドロ−2h−3−オキサ−6−アザ−as−インダセン化合物
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2012041898A1 (en) * 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
KR101576589B1 (ko) * 2011-06-01 2015-12-10 주식회사 녹십자 Sglt2 억제제로서의 신규한 다이페닐메탄 유도체
US9340521B2 (en) * 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
FR3017868A1 (fr) * 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
JP2019521985A (ja) 2019-08-08
DK3473621T3 (da) 2021-09-06
MA44545B1 (fr) 2020-05-29
JP6763978B2 (ja) 2020-09-30
TN2018000437A1 (en) 2020-06-15
SA518400666B1 (ar) 2021-11-30
PE20190467A1 (es) 2019-04-04
CA3081033A1 (en) 2017-12-21
KR20210036892A (ko) 2021-04-05
CN109311861A (zh) 2019-02-05
CN109311861B (zh) 2021-08-24
CN113651803B (zh) 2022-10-28
NZ749398A (en) 2020-01-31
HRP20211670T1 (hr) 2022-02-18
CA3026756C (en) 2021-03-02
RS62550B1 (sr) 2021-12-31
PT3473621T (pt) 2021-10-04
BR112018076243A2 (pt) 2019-03-26
EP3473621A1 (en) 2019-04-24
US20190169174A1 (en) 2019-06-06
SG10201911782RA (en) 2020-02-27
MX2021008988A (es) 2022-05-05
EP3473621A4 (en) 2020-03-11
US20190382390A1 (en) 2019-12-19
MA50774A1 (fr) 2021-03-31
DOP2018000287A (es) 2019-03-31
JP7352509B2 (ja) 2023-09-28
SI3663292T1 (sl) 2022-01-31
AU2017285813B2 (en) 2020-02-06
MA44545B2 (fr) 2020-11-30
PL3473621T3 (pl) 2022-01-10
PL3663292T3 (pl) 2022-01-17
PT3663292T (pt) 2021-11-08
EP3663292B1 (en) 2021-09-01
KR20170142904A (ko) 2017-12-28
MA50774B1 (fr) 2022-02-28
ECSP19000185A (es) 2019-01-31
DK3663292T3 (da) 2021-10-25
JP2023145481A (ja) 2023-10-11
CO2018014018A2 (es) 2019-03-08
US10889574B2 (en) 2021-01-12
EP3663292A1 (en) 2020-06-10
US10640496B2 (en) 2020-05-05
JP2021152054A (ja) 2021-09-30
RU2019101056A (ru) 2020-07-17
PH12018550206A1 (en) 2019-09-30
CL2018003645A1 (es) 2019-03-22
RU2019101056A3 (ko) 2020-07-17
PE20240590A1 (es) 2024-03-21
JP2020117528A (ja) 2020-08-06
RU2021129636A (ru) 2021-11-22
KR102233229B1 (ko) 2021-03-29
AU2017285813A1 (en) 2019-01-17
CA3026756A1 (en) 2017-12-21
CA3081033C (en) 2022-04-12
MA44545A1 (fr) 2019-10-31
ES2898336T3 (es) 2022-03-07
WO2017217792A1 (ko) 2017-12-21
HUE056428T2 (hu) 2022-02-28
EP3473621B1 (en) 2021-08-04
CN113651803A (zh) 2021-11-16
KR102379584B1 (ko) 2022-03-29
HRP20211670T8 (hr) 2022-03-18
ES2891825T3 (es) 2022-01-31
MX2018015647A (es) 2019-04-11

Similar Documents

Publication Publication Date Title
SG10201911782RA (en) Method for producing diphenylmethane derivative
PT3352896T (pt) Método de produção de isocianatos
EP3333266A4 (en) PROCESS FOR THE PRODUCTION OF SELENOEINE
IL266044B (en) Method for the production of 3-alkylsulfanyl-2-chloro-n-(1-alkyl-h1-tetrazol-5-yl)-4-trifluoromethyl-benzamides
PL3227023T3 (pl) Sposób wytwarzania kropel
EP3666729C0 (en) PROCESS FOR THE PRODUCTION OF NANO-SULFUR
EP3561067A4 (en) METHOD FOR MANUFACTURING UROLITHIN
PT3206518T (pt) Um pezinho de meia assim como um método para produzir esse pezinho de meia
EP3296282A4 (en) METHOD FOR PRODUCING HYDROHALOGEN FLUOROLEFINES
IL252173A0 (en) Methods for the production of methyl dichlorophosphane
EP3275886A4 (en) Method for producing dialkylaminosilane
SG11201701326YA (en) Method for producing oligosilane
IL264307B (en) Production method for a pyrazole-amide compound
HK1249098A1 (zh) 用於生產氟美他酚的方法
HK1256031A1 (zh) 新的4-苯並偶氮寧衍生物的製造方法
EP3118194A4 (en) Method for producing 2-acyliminopyridine derivative
EP3415499A4 (en) PROCESS FOR PREPARING 1-METHYLPYRROLIDIN-3-OL
HUE047039T2 (hu) Eljárás izocianátok elõállítására
SG11202004021RA (en) Production method for dihydroxyindoles
ZA201805537B (en) Method for producing sulfoxide derivative
SG11201907182QA (en) Method for producing perfluoroalkadiene compounds
IL255093A0 (en) A method for the production of levoglucosenon
PL3448159T3 (pl) Sposób wytwarzania niesmażonych nuggetów
PL3511315T3 (pl) Sposób wytwarzania n-metylo-para-anizydyny
EP3398929A4 (en) PROCESS FOR PREPARING ALPHA-ALPHA-DIFLUORACETALDEHYDE